Sponsored Webinars

Webinar 01 – Allograft Surveillance with dd-cfDNA Testing: Assessment of Rejection Risk 

This webinar covers the following topics –

• Surveillance after allograft transplantation is critical to the detection of active rejection and prevention of chronic allograft dysfunction.
• Levels of donor derive cell-free DNA (dd-cfDNA) have been observed significantly increased in active rejection versus stable patients, which is related to differences on allograft injury compared to a normal healthy status.
• By using single-nucleotide polymorphisms (SNPs) to discriminate between donor and recipient cfDNA molecules, AlloSeq cfDNA assay measures dd-cfDNA based as a clinical-grade, next-generation targeted sequencing (NGS) assay.
• Measurement of plasma dd-cfDNA at consecutive time points after transplant is a clinically useful tool for the assessment of allograft health and non-invasive surveillance for injury.
• Negative results are strongly supportive of no active injury (high NPV of 95%) and can give patients peace of mind. For transplant physicians, the test offers an opportunity to rule out rejection, and prioritize patients based on low risk for tele-medicine approaches.

Webinar 02 – Innovation in Action: Kit Based Solution by NGS to Detect dd-cfDNA for Transplant Surveillance

This webinar covers the following topics –

• Adopting the Latest Innovations in Molecular Transplant Surveillance
• Multi-Center Analytical Performance Validation of an IVD (D) Assay to Quantify dd-cfDNA in Solid Organ Transplant Recipient
• AlloSeq cfDNA Testing Platform Workflow and Laboratory Experience

These webinars have been designed and supported by CareDx and are hosted by ESOT.